GIA
ANIK icon

GHP Investment Advisors’s Anika Therapeutics ANIK Stock Holding History

GHP Investment Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$644 Hold
44
– – ﹤0.01% 1058
2026
Q1 		$638 Buy
+44
New +$511 ﹤0.01% 1086

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

GHP Investment Advisors's ANIK Position: Q2 2026 in Review

GHP Investment Advisors held its Anika Therapeutics (ANIK) position steady in Q2 2026 at 44 shares worth $644. The position accounts for ﹤0.01% of the portfolio, ranked #1058.

GHP Investment Advisors first reported a position in ANIK in Q1 2026 and has held it in 2 quarters since. 133 funds tracked by Wall St. Rank hold ANIK as of Q2 2026.

  • GHP Investment Advisors held 44 shares of Anika Therapeutics worth $644 as of Q2 2026.
  • GHP Investment Advisors left its Anika Therapeutics share count unchanged in Q2 2026.
  • Anika Therapeutics made up ﹤0.01% of GHP Investment Advisors's portfolio in Q2 2026, its #1058 holding.
  • GHP Investment Advisors first reported a position in Anika Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 133 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2026.

Based on GHP Investment Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.